Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sabra Health Care REIT (SBRA)

Sabra Q4 2025 net income falls to $0.11 a share; revenue rises to $211.9 million

Mixed Impact 3 of 5 earnings Written later

Sabra Health Care REIT reported fourth quarter 2025 total revenues of $211.9 million, up from $182.3 million a year earlier, but diluted net income fell to $0.11 per share from $0.19. Normalized FFO rose to $0.36 per share from $0.35 and normalized AFFO rose to $0.38 from $0.36. The company also initiated 2026 guidance for normalized FFO of $1.49 to $1.53 per share and normalized AFFO of $1.55 to $1.59 per share.

Key points

  • Q4 2025 diluted net income $0.11 per share vs $0.19 in Q4 2024; net loss on sales of real estate was $9.1 million in the quarter
  • Q4 2025 normalized FFO $0.36 per share vs $0.35; normalized AFFO $0.38 vs $0.36
  • 2026 guidance: net income $0.60 to $0.64 per share; normalized FFO $1.49 to $1.53; normalized AFFO $1.55 to $1.59
  • Board declared a quarterly dividend of $0.30 per share, payable February 27, 2026 to holders of record on February 13, 2026

The filing

CompanySabra Health Care REIT (SBRA)
Form8-K, current report
Filed with the SECFeb 12, 2026, 4:05 PM ET
Accession number0001492298-26-000007

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.